CD79A and nasopharyngeal carcinoma: Seroepidemiologic studies have proved that NPC patients have significantly higher levels of antibodies against EBV antigens, e.g. IgA antibodies against viral capsid antigen (VCA/IgA) and early antigen (EA/IgA).